Real-World Overall Survival of Multiple Myeloma Patients in a Colombian HMO During 2015-2023
Author(s)
Juan Manuel Reyes Sanchez, MSc1, Leonardo Jose Enciso Olivera, MD2, Farley Gonzalez, MSc2, Jair A. Arciniegas, MSc1, Luz E. Perez Jaramillo, MSc2, Andreina J. Alamo, BSc1, Carlos Bello, Pharm2, Mónica García, MSc1, Brigitte Alejandra Alarcon, MD1, Jhon E. Bolaños, MSc, MD2;
1Pfizer, Bogotá, Colombia, 2Biociencias-Sura, Medellín, Colombia
1Pfizer, Bogotá, Colombia, 2Biociencias-Sura, Medellín, Colombia
Presentation Documents
OBJECTIVES: To estimate the overall survival (OS) of multiple myeloma (MM) patients in a Colombian Health Maintenance Organization (HMO) between 2015-2023.
METHODS: A retrospective, descriptive cohort study of MM patients from 2015 to 2023 was conducted. Patients with the ICD-10 code C90.0 were included. The index date was when MM was diagnosed, and patients were followed until death, insurance discontinuation, or December 31, 2023, whichever occurred first. Demographics, treatment, and medical care were assessed at the index and during follow-up. Data were extracted from HMO administrative health records. Kaplan-Meier analyses was conducted to estimate the median survival.
RESULTS: A total of 700 patients were included. At index, these patients were older than 60 years (median: 64, IQR 16, Q1-Q3: 55-71) with late-stage disease (49.3% were at III-stage per ISS). Over 82% presented with a skeletal event and pathologic fractures (48.8%), hypercalcemia (26.2%), spinal cord compressions (19.3%) were also common; the median Charlson Comorbidity Index was 3 (IQR 3). 41.7% patients received autologous transplantation (AT). The median OS (mOS) was 6.5 years, though this varied by those with (10.2 years) and without (5.0 years) AT. Median OS varied considerable by ECOG performance score as well: 0 (10.6% patients) = not reached; 1 (50.9%) = 7.2 years; 2 (30%) = 6.6 years; 3 (7.7%) = 4.1 years; and 4 (0.9%) = 1.1 years. Similarly, mOS also varied by ISS: Stage I (14%) = 7.9 years; Stage II (36.7%) = 6.8 years; Stage III (49.3%) = 6.4 years. mOS also significantly varied by history of dialysis (hazard ratio = 2.1, 95% confidence interval: 1.45 - 2.98).
CONCLUSIONS: The mOS of Colombian MM patients was over six years. However, there are several clinical variables that were associated to the time of survival such as AT, ECOG, ISS, dialysis, among others.
METHODS: A retrospective, descriptive cohort study of MM patients from 2015 to 2023 was conducted. Patients with the ICD-10 code C90.0 were included. The index date was when MM was diagnosed, and patients were followed until death, insurance discontinuation, or December 31, 2023, whichever occurred first. Demographics, treatment, and medical care were assessed at the index and during follow-up. Data were extracted from HMO administrative health records. Kaplan-Meier analyses was conducted to estimate the median survival.
RESULTS: A total of 700 patients were included. At index, these patients were older than 60 years (median: 64, IQR 16, Q1-Q3: 55-71) with late-stage disease (49.3% were at III-stage per ISS). Over 82% presented with a skeletal event and pathologic fractures (48.8%), hypercalcemia (26.2%), spinal cord compressions (19.3%) were also common; the median Charlson Comorbidity Index was 3 (IQR 3). 41.7% patients received autologous transplantation (AT). The median OS (mOS) was 6.5 years, though this varied by those with (10.2 years) and without (5.0 years) AT. Median OS varied considerable by ECOG performance score as well: 0 (10.6% patients) = not reached; 1 (50.9%) = 7.2 years; 2 (30%) = 6.6 years; 3 (7.7%) = 4.1 years; and 4 (0.9%) = 1.1 years. Similarly, mOS also varied by ISS: Stage I (14%) = 7.9 years; Stage II (36.7%) = 6.8 years; Stage III (49.3%) = 6.4 years. mOS also significantly varied by history of dialysis (hazard ratio = 2.1, 95% confidence interval: 1.45 - 2.98).
CONCLUSIONS: The mOS of Colombian MM patients was over six years. However, there are several clinical variables that were associated to the time of survival such as AT, ECOG, ISS, dialysis, among others.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO20
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Oncology